Dr Reddys Laboratories Stock Performance
RDY Stock | USD 75.49 0.25 0.33% |
On a scale of 0 to 100, Dr Reddys holds a performance score of 14. The firm owns a Beta (Systematic Risk) of 0.29, which means not very significant fluctuations relative to the market. As returns on the market increase, Dr Reddys returns are expected to increase less than the market. However, during the bear market, the loss on holding Dr Reddys will be expected to be smaller as well. Although it is important to respect Dr Reddys Laboratories existing price patterns, it is better to be realistic regarding the information on the equity's price patterns. Please utilizes Dr Reddys Laboratories value at risk, and the relationship between the standard deviation and kurtosis to make a quick decision on whether Dr Reddys Laboratories current price history will revert.
Risk-Adjusted Performance
14 of 100
Low | High |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Dr Reddys Laboratories are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Dr Reddys showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.33 | Five Day Return 0.25 | Year To Date Return 6.58 | Ten Year Return 64.25 | All Time Return 1.4 K |
Forward Dividend Yield 0.0065 | Payout Ratio 0.0056 | Last Split Factor 2:1 | Forward Dividend Rate 0.49 | Dividend Date 2023-08-11 |
1 | Doctor Reddys Fiscal Q3 Earnings Snapshot | 01/31/2024 |
2 | Are You a Value Investor This 1 Stock Could Be the Perfect Pick | 02/08/2024 |
3 | Heres Why Doctor Reddys is a Strong Momentum Stock | 02/23/2024 |
4 | Dr. Reddys Laboratories underperforms Thursday when compared to competitors | 02/29/2024 |
5 | Dr. Reddys Laboratories falls Friday, underperforms market | 03/01/2024 |
6 | CVS Groups Buy Rating Reaffirmed at Berenberg Bank | 03/04/2024 |
7 | Hepatic Encephalopathy Market to Witness Robust Growth, Reaching 2.1 Billion by 2028 As Per The Business Research Companys Hepatic Encephalopathy Global Market ... | 03/06/2024 |
8 | Ramirez Asset Management Inc. Invests 1.68 Million in Dr. Reddys Laboratories Limited | 03/07/2024 |
9 | India stocks lower at close of trade Nifty 50 down 0.72 | 03/11/2024 |
10 | Global Vitamin B12 Market Size To Exceed USD 0.59 Billion By 2033 CAGR of 8.54 | 03/13/2024 |
11 | Dr. Reddys Laboratories Share Price Today Live Updates Dr. Reddys Laboratories Sees 0.81 percent Increase in... - Economic Times | 03/18/2024 |
Begin Period Cash Flow | 14.9 B | |
Total Cashflows From Investing Activities | -41.4 B |
RDY |
Dr Reddys Relative Risk vs. Return Landscape
If you would invest 6,637 in Dr Reddys Laboratories on December 20, 2023 and sell it today you would earn a total of 912.00 from holding Dr Reddys Laboratories or generate 13.74% return on investment over 90 days. Dr Reddys Laboratories is generating 0.2219% of daily returns assuming volatility of 1.1996% on return distribution over 90 days investment horizon. In other words, 10% of stocks are less volatile than RDY, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
Risk |
Dr Reddys Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dr Reddys' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dr Reddys Laboratories, and traders can use it to determine the average amount a Dr Reddys' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.185
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | RDY | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
1.2 actual daily | 10 90% of assets are more volatile |
Expected Return
0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
0.19 actual daily | 14 86% of assets perform better |
Based on monthly moving average Dr Reddys is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dr Reddys by adding it to a well-diversified portfolio.
Dr Reddys Fundamentals Growth
RDY Stock prices reflect investors' perceptions of the future prospects and financial health of Dr Reddys, and Dr Reddys fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RDY Stock performance.
Return On Equity | 0.21 | ||||
Return On Asset | 0.12 | ||||
Current Valuation | 11.98 B | ||||
Shares Outstanding | 166.52 M | ||||
Price To Earning | 31.58 X | ||||
Price To Book | 3.87 X | ||||
Price To Sales | 0.05 X | ||||
Revenue | 245.88 B | ||||
Gross Profit | 113.84 B | ||||
EBITDA | 108.78 B | ||||
Net Income | 60.48 B | ||||
Cash And Equivalents | 2.93 B | ||||
Cash Per Share | 208.58 X | ||||
Debt To Equity | 0.12 % | ||||
Current Ratio | 1.98 X | ||||
Cash Flow From Operations | 58.87 B | ||||
Earnings Per Share | 3.78 X | ||||
Total Asset | 322.85 B | ||||
Retained Earnings | 215.59 B | ||||
Current Asset | 1.81 B | ||||
About Dr Reddys Performance
To evaluate Dr Reddys Laboratories Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Dr Reddys generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare RDY Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Dr Reddys Laboratories market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents RDY's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.37 | 0.38 | |
Return On Assets | 0.16 | 0.09 | |
Return On Equity | 0.22 | 0.14 |
Things to note about Dr Reddys Laboratories performance evaluation
Checking the ongoing alerts about Dr Reddys for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dr Reddys Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Latest headline from news.google.com: Dr. Reddys Laboratories Share Price Today Live Updates Dr. Reddys Laboratories Sees 0.81 percent Increase in... - Economic Times |
- Analyzing Dr Reddys' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dr Reddys' stock is overvalued or undervalued compared to its peers.
- Examining Dr Reddys' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dr Reddys' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dr Reddys' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dr Reddys' stock. These opinions can provide insight into Dr Reddys' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.78 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.